Evaluation of Preexisting Immunity Markers in Human Tumor Tissue Sample

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00568867

Enrollment

300

Registered

2007-12-06

Start date

2006-09-30

Completion date

2008-12-31

Last updated

2011-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Brief summary

The purpose of this study is to evaluate markers of immune response in human tumor samples.

Detailed description

Cancer immunotherapy has been shown to be effective in isolated instances, but ineffective in most patients. The reason for this inconsistency, and the conditions necessary for successful immunotherapy, are not well understood. Our studies in animal tumor models indicate that the effectiveness of IL-12-based immunotherapy depends upon the presence of a preexisting immune response to the tumor. The presence of T cell infiltrates and IFN-gamma expression in tumor indicate such an immune response. We therefore plan to evaluate the existing immune response in human tumor samples in an effort to identify those patients most likely to respond to therapy with IL-12.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Any adult patient with a tumor who is scheduled to undergo surgery to either remove or biopsy the tumor.

Exclusion criteria

Patients without tumor and pediatric patients (children) will be excluded.

Countries

United States

Outcome results